38.43
price up icon6.75%   2.43
after-market Handel nachbörslich: 37.82 -0.61 -1.59%
loading
Schlusskurs vom Vortag:
$36.00
Offen:
$38.05
24-Stunden-Volumen:
124.06K
Relative Volume:
1.13
Marktkapitalisierung:
$424.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+35.22%
1M Leistung:
+70.50%
6M Leistung:
+195.84%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$37.81
$38.74
1-Wochen-Bereich:
Value
$28.19
$38.74
52-Wochen-Spanne:
Value
$11.17
$38.74

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name
Firmenname
Palvella Therapeutics Inc
Name
Telefon
(484) 253-1461
Name
Adresse
125 STRAFFORD AVE, WAYNE
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
PVLA's Discussions on Twitter

Vergleichen Sie PVLA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PVLA
Palvella Therapeutics Inc
38.43 398.00M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-21 Eingeleitet Truist Buy
2025-04-09 Eingeleitet Chardan Capital Markets Buy
2025-03-26 Eingeleitet Stifel Buy
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2025-02-20 Eingeleitet Canaccord Genuity Buy
2025-02-05 Eingeleitet TD Cowen Buy
2024-12-26 Eingeleitet H.C. Wainwright Buy
2024-12-18 Eingeleitet Cantor Fitzgerald Overweight
2020-03-13 Hochstufung Robert W. Baird Neutral → Outperform
2019-07-30 Herabstufung Robert W. Baird Outperform → Neutral
2019-05-14 Eingeleitet Robert W. Baird Outperform
2018-03-19 Eingeleitet Evercore ISI Outperform
2018-03-19 Eingeleitet Jefferies Buy
2018-01-16 Bestätigt H.C. Wainwright Buy
2017-05-30 Eingeleitet Rodman & Renshaw Buy
2016-08-05 Fortgesetzt ROTH Capital Buy
2015-08-12 Eingeleitet JMP Securities Mkt Outperform
2015-07-27 Eingeleitet Oppenheimer Outperform
2015-07-22 Eingeleitet ROTH Capital Buy
Alle ansehen

Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten

pulisher
06:01 AM

Palvella Therapeutics Inc. Stock Analysis and ForecastOutstanding capital appreciation - Autocar Professional

06:01 AM
pulisher
09:41 AM

Palvella Therapeutics Inc (PVLA) Stock: A Year of Highs and Lows in the Market - investchronicle.com

09:41 AM
pulisher
09:32 AM

A Great Week for Institutional Investors Who Own 27% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - 富途牛牛

09:32 AM
pulisher
05:33 AM

Is Palvella Therapeutics Inc. a good long term investmentHigh-yield portfolio picks - Autocar Professional

05:33 AM
pulisher
Jul 22, 2025

What analysts say about Palvella Therapeutics Inc. stockHigh-yield portfolio picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Truist Securities initiates Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Palvella Therapeutics Inc. stock priceSuperior stock growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

What makes Palvella Therapeutics Inc. stock price move sharplyLow Risk Consistent Winners - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Palvella Therapeutics Inc. stock attracts strong analyst attentionLow Risk Entry Points - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Palvella Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN

Jul 11, 2025
pulisher
Jul 09, 2025

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin - Insider Monkey

Jul 09, 2025
pulisher
Jul 04, 2025

Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - simplywall.st

Jul 04, 2025
pulisher
Jul 03, 2025

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jul 03, 2025
pulisher
Jul 02, 2025

2,516 Shares in Palvella Therapeutics, Inc. (NASDAQ:PVLA) Purchased by Spire Wealth Management - Defense World

Jul 02, 2025
pulisher
Jul 01, 2025

Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Jul 01, 2025
pulisher
Jun 30, 2025

Palvella Therapeutics, Inc.(NasdaqCM: PVLA) added to Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Palvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025 - Nasdaq

Jun 30, 2025
pulisher
Jun 24, 2025

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin - MyChesCo

Jun 24, 2025
pulisher
Jun 23, 2025

Breakthrough Therapy: Phase 3 Trial Exceeds Target by 25% for First-Ever Microcystic LM Treatment - Stock Titan

Jun 23, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan

Jun 18, 2025
pulisher
Jun 12, 2025

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World

Jun 09, 2025
pulisher
Jun 01, 2025

Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN

Jun 01, 2025
pulisher
May 30, 2025

Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks

May 30, 2025
pulisher
May 30, 2025

A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st

May 30, 2025

Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)

Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):